2010
Biological effects of combined ultrasound and cisplatin treatment on ovarian carcinoma cells
BERNARD, Vladan; Jiřina ŠKORPÍKOVÁ; Vojtěch MORNSTEIN a Iva SLANINOVÁZákladní údaje
Originální název
Biological effects of combined ultrasound and cisplatin treatment on ovarian carcinoma cells
Vydání
Ultrasonics, 2010, 0041-624X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
10610 Biophysics
Stát vydavatele
Nizozemské království
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 1.599
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14110/10:00043266
Organizační jednotka
Lékařská fakulta
UT WoS
Klíčová slova anglicky
Carcinoma cells; Cisplatin; Ultrasound; Viability; MTT test
Změněno: 12. 1. 2011 12:31, doc. Mgr. Vladan Bernard, Ph.D.
Anotace
V originále
Abstract- The effects of low-power ultrasound, the anti-cancer drug cisplatin, and their combined application were studied in two lines of human ovarian carcinoma cells, A2780 and A2780cis. Four modes of treatment were used: exposure to ultrasonic field, application of cisplatin, exposure to ultrasound followed by cisplatin, and presence of cisplatin followed by exposure to application ultrasound. Ultrasound was used at intensities of 0.5 W/cm(2) and 1.0 W/cm(2) for 10 min, cisplatin was applied at concentrations of 1 mu M and 6 mu M per cell suspension treated in A2780 and cisplatin-resistant A2780cis cells, respectively. The results of each experimental treatment were assessed by the resultant cell viability related to the viability of control cells, using a standard MTT test. It was shown that a combined effect of ultrasound and cisplatin was more effective than that of ultrasound or cisplatin alone. It also appeared that the order of application played a role, with the cisplatin-ultrasound treatment lowering cell viability more than the ultrasound-cisplatin treatment. It can be assumed that the exposure of cells to a low-power ultrasonic field has an immediate effect on the structure of cell surfaces and, consequently, on entry of cisplatin into the cell.
Návaznosti
| GA305/05/2030, projekt VaV |
| ||
| LC06077, projekt VaV |
| ||
| MUNI/C/0092/2009, interní kód MU |
|